These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15602125)

  • 1. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-Infected patients in a population-based cohort.
    Kuyper LM; Wood E; Montaner JS; Yip B; O'connell JM; Hogg RS
    J Acquir Immune Defic Syndr; 2004 Dec; 37(4):1470-6. PubMed ID: 15602125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
    Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
    CMAJ; 2003 Sep; 169(7):656-61. PubMed ID: 14517122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting.
    Nolan S; Milloy MJ; Zhang R; Kerr T; Hogg RS; Montaner JS; Wood E
    AIDS Care; 2011 Aug; 23(8):980-7. PubMed ID: 21480010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why are baseline HIV RNA levels 100,000 copies/mL or greater associated with mortality after the initiation of antiretroviral therapy?
    Wood E; Hogg RS; Yip B; Harrigan PR; Montaner JS
    J Acquir Immune Defic Syndr; 2005 Mar; 38(3):289-95. PubMed ID: 15735446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting.
    Ladak F; Socias E; Nolan S; Dong H; Kerr T; Wood E; Montaner J; Milloy MJ
    Antivir Ther; 2019; 24(1):19-25. PubMed ID: 30230474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use.
    Palepu A; Tyndall M; Yip B; O'Shaughnessy MV; Hogg RS; Montaner JS
    J Acquir Immune Defic Syndr; 2003 Apr; 32(5):522-6. PubMed ID: 12679704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy.
    Doyle T; Smith C; Vitiello P; Cambiano V; Johnson M; Owen A; Phillips AN; Geretti AM
    Clin Infect Dis; 2012 Mar; 54(5):724-32. PubMed ID: 22238167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme.
    Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
    HIV Med; 2007 Mar; 8(2):80-5. PubMed ID: 17352763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
    Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
    Ann Intern Med; 2003 Nov; 139(10):810-6. PubMed ID: 14623618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
    Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
    AIDS; 2006 May; 20(8):1117-23. PubMed ID: 16691062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.
    Paredes R; Mocroft A; Kirk O; Lazzarin A; Barton SE; van Lunzen J; Katzenstein TL; Antunes F; Lundgren JD; Clotet B
    Arch Intern Med; 2000 Apr; 160(8):1123-32. PubMed ID: 10789605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users.
    Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
    Antivir Ther; 2004 Apr; 9(2):229-35. PubMed ID: 15134185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naïve HIV-infected individuals initiating combination antiretroviral therapy.
    Raboud J; Blitz S; Walmsley S; Thompson C; Rourke SB; Loutfy MR;
    HIV Clin Trials; 2010; 11(6):340-50. PubMed ID: 21239362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.
    Rodríguez-Arenas MA; Jarrín I; del Amo J; Iribarren JA; Moreno S; Viciana P; Peña A; Sirvent JL; Vidal F; Lacruz J; Gutierrez F; Oteo JA; Asencio R; Castilla J; Hoyos SP;
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):715-23. PubMed ID: 16910826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receipt of opioid agonist treatment halves the risk of HIV-1 RNA viral load rebound through improved ART adherence for HIV-infected women who use illicit drugs.
    Adams JW; Marshall BDL; Mohd Salleh NA; Barrios R; Nolan S; Milloy MJ
    Drug Alcohol Depend; 2020 Jan; 206():107670. PubMed ID: 31711873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.
    Phillips AN; Staszewski S; Lampe F; Youle MS; Klauke S; Bickel M; Sabin CA; Doerr HW; Johnson MA; Loveday C; Miller V; ;
    J Infect Dis; 2002 Oct; 186(8):1086-91. PubMed ID: 12355358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study.
    Barber TJ; Geretti AM; Anderson J; Schwenk A; Phillips AN; Bansi L; Gilson R; Hill T; Walsh J; Fisher M; Johnson M; Post F; Easterbrook P; Gazzard B; Palfreeman A; Orkin C; Leen C; Gompels M; Dunn D; Delpech V; Pillay D; Sabin CA;
    Antivir Ther; 2011; 16(6):805-14. PubMed ID: 21900712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy.
    Pence BW; Miller WC; Gaynes BN; Eron JJ
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):159-66. PubMed ID: 17146374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.